Immunic, Inc. Announces $5.1 Million Direct Offering Guided by Aberdeen Investments

On April 9, 2025, Immunic, Inc., a biotechnology firm listed on Nasdaq as IMUX, publicized a registered direct offering of its common stock. The offering consists of 5,666,667 shares priced at $0.90 each, led by Aberdeen Investments, expected to generate approximately $5.1 million in gross proceeds before deducting expenses. Completion of the offering is anticipated by April 10, 2025, following customary conditions.

The proceeds from the offering are allocated for clinical trials, operational costs, and corporate needs. Titan Partners Group is the sole placement agent. The offering is underpinned by a previously filed shelf registration statement with the SEC. It underscores Immunic’s ongoing commitment to developing therapies for chronic inflammatory and autoimmune diseases.